EMG
CTMX icon

Ellington Management Group’s CytomX Therapeutics CTMX Stock Holding History

Ellington Management Group’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,100
Closed -$104K – 558
2019
Q3 		$104K Buy
+14,100
New +$139K 0.02% 553

Other funds holding CTMX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ellington Management Group's CTMX Position: Q4 2019 in Review

Ellington Management Group sold out of CytomX Therapeutics (CTMX) in Q4 2019, closing a stake of 14,100 shares — an estimated $104K sold.

Ellington Management Group first reported a position in CTMX in Q3 2019 and held it in 1 quarter. The position peaked at $104K in Q3 2019. 119 funds tracked by Wall St. Rank hold CTMX as of Q4 2019.

  • Ellington Management Group reported no remaining CytomX Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Ellington Management Group sold 14,100 CytomX Therapeutics shares in Q4 2019, an estimated $104K.
  • Ellington Management Group first reported a position in CytomX Therapeutics in Q3 2019 and held it in 1 quarter.
  • Ellington Management Group's CytomX Therapeutics position peaked at $104K in Q3 2019.
  • 119 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2019.

Based on Ellington Management Group's 13F filing for Q4 2019, filed 14 Feb 2020.